Genetic Variations of
NSCLC
SNP
prognosis
risk
rs10849448
rs1883832
rs7290134
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
06
2021
accepted:
10
08
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
5
10
2021
Statut:
epublish
Résumé
Immune system-related receptors CD40 (tumor necrosis factor receptor superfamily member 5), BAFFR (tumor necrosis factor receptor superfamily member 13C), and LTβR (tumor necrosis factor receptor superfamily member 3) play a pivotal role in non-small-cell lung cancer (NSCLC). To further evaluate their role in NSCLC, The three selected SNPs were evaluated in 229 NSCLC patients and 299 healthy controls, while CD40, BAFFR, and LTβR protein expression was assessed by immunohistochemistry in 96 tumor specimens from NSCLC patients. In total, In conclusion,
Sections du résumé
BACKGROUND
BACKGROUND
Immune system-related receptors CD40 (tumor necrosis factor receptor superfamily member 5), BAFFR (tumor necrosis factor receptor superfamily member 13C), and LTβR (tumor necrosis factor receptor superfamily member 3) play a pivotal role in non-small-cell lung cancer (NSCLC). To further evaluate their role in NSCLC,
METHODS
METHODS
The three selected SNPs were evaluated in 229 NSCLC patients and 299 healthy controls, while CD40, BAFFR, and LTβR protein expression was assessed by immunohistochemistry in 96 tumor specimens from NSCLC patients.
RESULTS
RESULTS
In total,
CONCLUSIONS
CONCLUSIONS
In conclusion,
Identifiants
pubmed: 34604057
doi: 10.3389/fonc.2021.721577
pmc: PMC8484958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
721577Informations de copyright
Copyright © 2021 Dimitrakopoulos, Antonacopoulou, Kottorou, Kalofonou, Panagopoulos, Dougenis, Makatsoris, Tzelepi, Koutras and Kalofonos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomed Pharmacother. 2020 Oct;130:110569
pubmed: 32750649
Nat Commun. 2017 Sep 19;8(1):599
pubmed: 28928442
Cancer. 2006 Dec 1;107(11):2637-46
pubmed: 17078054
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Endocr J. 2005 Aug;52(4):471-7
pubmed: 16127217
J Obstet Gynaecol Res. 2017 May;43(5):923-928
pubmed: 28181356
Blood. 2008 Apr 15;111(8):4348-54
pubmed: 18287517
PLoS One. 2011;6(8):e23762
pubmed: 21912605
Virchows Arch. 2012 May;460(5):515-23
pubmed: 22562129
Tissue Antigens. 2015 Oct;86(4):279-84
pubmed: 26268376
DNA Cell Biol. 2011 Mar;30(3):173-8
pubmed: 21091218
Biomed Pharmacother. 2010 Mar;64(3):191-4
pubmed: 20137882
Sci Rep. 2019 Oct 4;9(1):14299
pubmed: 31586084
Cell Physiol Biochem. 2015;35(1):83-91
pubmed: 25547203
PLoS One. 2014 May 14;9(5):e97289
pubmed: 24828072
Gene. 2013 Oct 25;529(2):257-61
pubmed: 23954880
J Clin Med. 2019 May 24;8(5):
pubmed: 31137630
Cancer Res. 2020 Oct 1;80(19):4025-4036
pubmed: 32616502
Cancer Immunol Immunother. 2000 May;49(2):101-8
pubmed: 10823420
Clin Chim Acta. 2009 Oct;408(1-2):56-9
pubmed: 19622350
Cancer. 2008 Aug 1;113(3):530-41
pubmed: 18548529
Nat Genet. 2013 Jun;45(6):664-9
pubmed: 23603761
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Int J Clin Exp Pathol. 2015 Nov 01;8(11):15163-9
pubmed: 26823861
Ann Thorac Surg. 2006 Jul;82(1):243-8
pubmed: 16798222
Tumour Biol. 2016 Oct;37(10):13617-13626
pubmed: 27468724
Endocrinology. 2005 Jun;146(6):2684-91
pubmed: 15731360